publication . Article . Other literature type . Report . 2018

Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock

Rawal, H. A.; Kocheril, A. G.;
Open Access
  • Published: 01 May 2018 Journal: Case Reports in Cardiology, volume 2,018, pages 1-3 (issn: 2090-6404, eissn: 2090-6412, Copyright policy)
  • Publisher: Hindawi Limited
Abstract
<jats:p>Sacubitril/valsartan is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for heart failure. We present a case of a patient with NYHA class IV systolic heart failure who was refractory to all other classes of heart failure medications and was started on this new medication. On sacubitril/valsartan, he developed cardiogenic shock. This led us to reevaluate the use and risks of this medication in the class IV heart failure population.</jats:p>
Subjects
free text keywords: Refractory, Renin–angiotensin system, Heart failure, medicine.disease, medicine, Cardiology, medicine.medical_specialty, Combination drug, Valsartan, medicine.drug, Cardiogenic shock, business.industry, business, Internal medicine, Population, education.field_of_study, education, Sacubitril, Diseases of the circulatory (Cardiovascular) system, RC666-701, Case Report, Article Subject
Related Organizations

Jessup, M., Abraham, W. T., Casey, D. E.. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. 2009; 119 (14): 1977-2016 [] [DOI]

Hunt, S. A., Abraham, W. T., Chin, M. H.. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. 2005; 112: e154-e235 [DOI]

McCormack, P. L.. Sacubitril/valsartan: a review in chronic heart failure with reduced ejection fraction. 2016; 76 (3): 387-396 [OpenAIRE] [] [DOI]

McMurray, J. J. V., Packer, M., Desai Akshay, S.. Angiotensin–neprilysin inhibition versus enalapril in heart failure. 2014; 371 (11): 993-1004 [] [DOI]

Mccarthy, C. P., McEvoy, J. W.. Let us not forget the long-term safety concerns of sacubitril/valsartan. 2017; 2 (7): p. 818 [OpenAIRE] [] [DOI]

Feldman, A. M., Haller, J. A., DeKosky, S. T.. Valsartan/sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations. 2017; 315 (1): p. 25 [OpenAIRE] [] [DOI]

Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . Other literature type . Report . 2018

Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock

Rawal, H. A.; Kocheril, A. G.;